Ignite Creation Date:
2024-05-06 @ 4:06 AM
Last Modification Date:
2024-10-26 @ 11:44 AM
Study NCT ID:
NCT02456701
Status:
COMPLETED
Last Update Posted:
2017-09-05
First Post:
2015-05-20
Brief Title:
Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379
Sponsor:
Celldex Therapeutics
Organization:
Celldex Therapeutics
Organization Data
Organization:
Celldex Therapeutics
Class:
INDUSTRY
Study ID:
KTN3379-CL-003
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Celldex Therapeutics
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Memorial Sloan Kettering Cancer Center | OTHER |